New study aims to make HIV prevention easier for black women
NCT ID NCT05514509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed phase 4 study looked at how to best offer cabotegravir PrEP (a long-acting injection and tablets) to Black cisgender and transgender women in the US who do not have HIV. About 370 women took part, and researchers measured how well different delivery strategies worked in real clinics. The goal was to find ways to make HIV prevention more accessible and acceptable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabotegravir (injection and tablet)
What this could lead to
If successful, this study could show that offering cabotegravir PrEP in different ways helps more Black women at risk of HIV get and stay on prevention.
What could go wrong
This is a completed implementation study, not a test of whether the drug works. The results may not apply to all settings or populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Washington D.C., District of Columbia, 20005, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20010, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20017, United States
-
GSK Investigational Site
Miami, Florida, 33137, United States
-
GSK Investigational Site
Orlando, Florida, 32808, United States
-
GSK Investigational Site
Tampa, Florida, 33611, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33401, United States
-
GSK Investigational Site
Atlanta, Georgia, 30303, United States
-
GSK Investigational Site
Atlanta, Georgia, 30309, United States
-
GSK Investigational Site
Atlanta, Georgia, 30312, United States
-
GSK Investigational Site
Bridgeport, Kansas, 06605, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89104, United States
-
GSK Investigational Site
Brooklyn, New York, 10001, United States
-
GSK Investigational Site
New York, New York, 10029, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19114, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19147, United States
-
GSK Investigational Site
Memphis, Tennessee, 38104, United States
-
GSK Investigational Site
Dallas, Texas, 75201, United States
-
GSK Investigational Site
Houston, Texas, 77006, United States
-
GSK Investigational Site
Houston, Texas, 77021, United States
-
GSK Investigational Site
Norfolk, Virginia, 23510, United States